HOME >> BIOLOGY >> NEWS
Introgens gene drug demonstrates tumor growth control

or that the proposed treatments will prove to be safe and/or effective. The actual results may differ from those described in this press release due to risks and uncertainties that exist in Introgens operations and business environment, including, but without limitation, Introgens stage of product development and the limited experience in the development of gene-based drugs in general, its dependence upon proprietary technology and current competition, history of operating losses and accumulated deficits, Introgens reliance on collaborative relationships, and uncertainties related to clinical trials, safety, efficacy, the ability to obtain the appropriate regulatory approvals, patent protection and market acceptance, as well as other risks detailed from time to time in Introgens filings with the Securities and Exchange Commission, including its prospectus dated October 12, 2000, filed with the Securities and Exchange Commission and the 10-K filed with the Securities and Exchange Commission on September 19, 2001. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising from the date hereof.


'"/>

Contact: Channing Burke
c.burke@introgen.com
512-708-9310
Porter Novelli
25-Oct-2001


Page: 1 2 3 4

Related biology news :

1. New genetic research demonstrates possible cause of inherited form of Parkinsons disease
2. Study demonstrates altered angiogenic proteins in preeclampsia patients
3. New study demonstrates bone protein can reverse kidney failure
4. Study demonstrates that low dose tamoxifen may be effective in treating breast cancer
5. Animal study demonstrates carbon monoxide may help heart patients
6. Binary enzyme created by TSRI scientists demonstrates Darwinian evolution at its simplest
7. New UGA study demonstrates bacterial pathogens use hydrogen as energy source in animals
8. Inhibitor of novel cancer target, LPAAT-beta, demonstrates selective anti-cancer effects
9. Norwegian study demonstrates targeted coxibs may prevent oral cancer
10. New physical activity opinion survey demonstrates perceptions do not meet reality
11. Testosterone gel (AndroGel) study demonstrates safety and efficacy up to 42 months

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Introgens gene drug demonstrates tumor growth control

(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now ... Length Gauge offerings with new variants of its successful ... HEIDENHAIN’s pencil probe-style SPECTO length gauge series now offers ... 1Vpp, 12mm stroke length variants of the SPECTO series ... variant with a weak spring, 0.4N of gauging force, ...
(Date:2/26/2015)... 2015  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technologies are used to develop, manufacture and sell ... chemical, biopharmaceutical and industrial enzyme industries, announced today ... year ending December 31, 2014 after market close ... a conference call that day at 5:00 p.m. ...
(Date:2/26/2015)... Feb. 26, 2015  Epic Sciences announced today that ... present at the 35th Annual Cowen and Company Health ... the MIT Room, 3rd Floor. The conference will be ... Mass. Epic is developing diagnostic tests of ... and proteomic changes that occur during the course of ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 On Wednesday, ... to building a nationwide Clostridium difficile (C. diff) awareness ... diff burden study by the Centers for Disease Control ... caused almost half a million infections among Americans in ... nursing homes. , The study also estimates that ...
Breaking Biology Technology:Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4
Cached News: